The effects of sulfated secondary bile acids on intestinal barrier function and immune response in an inflammatory in vitro human intestinal model

Benthe van der Lught, Maartje C.P. Vos, Mechteld Groote Bromhaar, Noortje Ijssennagger, Frank Vrieling, Jocelijn Meijerink, Wilma T. Steegenga

Department of Molecular Cancer Research, Center for Molecular Medicine, University Medical Center Utrecht, the Netherlands

Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, the Netherlands

1. Introduction

Inflammatory bowel disease (IBD) comprises a set of disorders that causes chronic and relapsing inflammation of the gastrointestinal tract. The etiology of IBD remains largely unknown, although it is clear that it is a multifactorial disease, in which the complex interplay between genetic susceptibility, environmental stimuli and the immune system are involved [1, 2]. Furthermore, the gut microbiota is thought to play a major role in the onset and progression of IBD, which is emphasized by studies showing that gut microbiota composition in IBD patients is dysbiotic [3, 4, 5, 6]. Dysbiosis is linked to disturbed intestinal barrier function, such as increased intestinal permeability [7] and an impaired mucus layer [8, 9]. Impaired intestinal barrier function enables direct bacterial contact with the epithelial cell layer, thereby inducing an inflammatory response [10, 11, 12, 13]. In a healthy situation, the intestinal mucosal immune system is tolerant against commensal bacteria, a process in which intestinal dendritic cells (DCs) play a crucial role [14, 15, 16]. During IBD, intestinal DCs have lost their tolerogenic function and produce elevated levels of pro-inflammatory cytokines, consequently leading to an exacerbated disease progression [17, 18].

Importantly, dysbiosis is also linked to an altered production of bacterial metabolites, such as secondary bile acids (BAs) [3, 19, 20, 21]. Primary BAs are synthesized in the liver, conjugated with taurine or glycine and secreted in the small intestine, where they accomplish a major role in lipid digestion [22]. BAs are actively reabsorbed in the ileum, transported back to the liver and metabolized by hepatic enzymes to be reused again, which is a process called the enterohepatic cycle [22]. Approximately 5% of all BAs are not reabsorbed and enter the colon, where resident bacteria deconjugate and metabolize them into secondary BAs. These secondary BAs can be either excreted via feces or reabsorbed and transported back to the liver. However, secondary BAs might be hepatotoxic at high concentrations and are therefore first detoxified by addition of a sulfonate group (SO3⁻) [23]. As a result of IBD-related dysbiosis, the production of bacterial enzymes and thus BA metabolism...
can be disturbed, a process known as BA dysmetabolism [24]. Indeed, the capacity of the gut microbiota to deconjugate BAs and transform primary to secondary BAs was decreased in patients with active IBD. As a consequence, increased abundance of conjugated BAs and decreased abundance of secondary BAs in feces of IBD patients during both remission and active disease was detected, as compared to healthy people [3, 25]. Similar differences in BA composition were found in other studies investigating fecal metabolite pools in IBD patients [19, 20, 26, 27]. Interestingly, dysbiosis in IBD patients was also associated with a reduced desulfation capacity, which was concomitant with 15% higher levels of fecal sulfated BAs [3]. Likewise, increased levels of fecal 3-sulfo- deoxycholic acid and chenodeoxycholic acid sulfate were found in Crohn’s disease patients [20]. The fecal abundance of sulfated BAs was also found to be elevated in patients with non-inflammatory intestinal disorders, such as diarrhea-predomninated irritable bowel syndrome [25, 28].

Given the important signaling functions of secondary BAs, including their role in inflammatory pathways, a change in luminal BA composition may have consequences on the progression of IBD. However, the possible involvement of sulfated BAs is only based on associative studies and the causal effects remain elusive. Therefore, the aim of this study was to investigate the effects of sulfated BAs on intestinal barrier function and immune response. Since existing models often insufficiently approach the physiological representation of the intestinal barrier and inflammatory environment in the context of IBD, we first established a novel inflammatory in vitro human intestinal model. We included a co-culture of Caco-2 and HT29-MTX-E12 cells, which are both human colon carcinoma cell lines representing an enterocyte and a mucus-producing cell line, respectively. To mimic the inflammatory state as observed during IBD, the co-culture was grown on cell culture inserts in combination with DCs in the basolateral compartment, which were activated with LPS to obtain pro-inflammatory properties. In contrast to existing models, our model had an improved mucus layer by growing the cells on a semi-wet interface with mechanical stimulation (SMWS) [29, 30]. After exposure to sulfated deoxycholic acid (DCA), sulfated lithocholic acid (LCA) and their unsulfated forms for 24 h, the effects on intestinal barrier function and immune response were investigated. New insights into the role of BA dysmetabolism in IBD may contribute to the discovery of novel therapies that may add to the treatment of IBD.

2. Materials and methods

2.1. Cell culture

Caco-2 cells (ATCC) and HT29-MTX-E12 cells (ECACC) were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% Fetal Bovine Serum and 1% penicillin/streptomycin. Cells were grown until 80–90% confluence at 37 °C/5% CO₂. Passage numbers between 7 and 25 were used for Caco-2 cells and between 3 and 15 for HT29-MTX-E12 cells. Monocytes were isolated fromuffy coat using LeucoSep tubes (Greiner-Bio One, Alphen aan den Rijn, The Netherlands), pre-isolated from the buffy coat using LeucoSep tubes (Greiner-Bio One, Alphen aan den Rijn, The Netherlands). First, PBMCs were isolated from blood donors (Sanquin, Nijmegen, The Netherlands).

2.2. Cell model

A co-culture of Caco-2 cells and HT29-MTX-E12 cells was seeded in 24-well ThinCert cell culture inserts with 0.4 μm pores (Greiner-Bio One, Alphen aan den Rijn, The Netherlands). Caco-2 and HT29-MTX-E12 cells were seeded in a 3:1 ratio, using a seeding density of 225,000 cells/mL in a volume of 150 μL. A volume of 700 μL DMEM was added to the basolateral compartment. Two days after seeding, media volumes were changed to 25 μL and 425 μL in the apical and basolateral compartment, respectively. The cell culture plates were put on a CO₂ resistant shaker (Thermo Fisher Scientific, Breda, The Netherlands) at 65 rpm. Cells were differentiated for 14 days and medium was changed every other day. Immature DCs were seeded in 24-wells plates in a density of 400,000 cells per well. DCs were stimulated with 10 ng/ml LPS at 150, Sigma-Aldrich, Darmstadt, Germany) for 24 h. Maturation of DCs was checked on the CytoFLEX Flow Cytometer (Beckman Coulter, Woerden, The Netherlands) using CD14-ECD antibody, clone RMO52 (IM2707 U, Beckman Coulter), FITC anti-human CD83, clone HB15e and PE/Cy7 anti-human CD209 (DC-SIGN), clone 9E9A8 antibodies (BioLegend, Amsterdam, The Netherlands). The culture inserts with Caco-2 and HT29-MTX-E12 cells were transferred to the cell culture plate containing the LPS-activated DCs, without changing of the LPS-containing DC culture medium. The co-culture was exposed to lithocholic acid 3-sulfate disodium salt (sulfo-LCA) (Santa-Cruz Biotechnology, Dallas, United States), deoxycholic acid 3-O-sulfate disodium salt (sulfo-DCA) (Toronto Research Chemicals, Toronto, Canada), lithocholic acid (LCA) and deoxycholic acid (DCA) (Sigma-Aldrich, Darmstadt, Germany). LCA and sulfo-LCA were solubilized in DMEM:methanol (1:1, v/v). DCA and sulfo-DCA were solubilized in DMEM:methanol (3:1, v/v). The concentrations of BAs used were based on physiological concentrations [3]. A control without DCs and a control with LPS-activated DCs were included. Control cells were exposed to similar concentrations of methanol (0.5%). Every condition was applied in duplicate. A total of three similar plates were seeded and exposed to BAs; plate 1 was used for permeability assays, plate 2 for RNA isolation and plate 3 for protein isolation. Experiments where DCs were directly exposed to BAs were performed similarly, except that BAs were applied directly to the DCs.

2.3. Quantification of lactate hydrogenase release

To investigate the effects of BA exposure on cytotoxicity of Caco-2 and HT29-MTX-E12 cells and DCs, lactate hydrogenase levels were measured in conditioned medium collected directly after 24 h of BA exposure. To this end, a lactate dehydrogenase (LDH) cytotoxicity detection kit (Roche Applied Science, Almere, The Netherlands) was used following the manufacturer’s instructions. As a control for complete cytotoxicity, cells were exposed for 15 min to a 1% Triton-X100 solution.

2.4. Trans- and paracellular epithelial permeability assays

Transepithelial resistance (TEER) was measured with an EVOM2 Volt/Ohm meter using STX2 electrodes (World Precision Instruments, Sarasota, United States). To assure the electrodes were fully submerged in medium, the media volumes were adapted to 100 μL apical and 700 μL basolateral before the first TEER measurements were performed. The TEER values after BA exposure were expressed as percentage of the TEER value measured just before BA exposure. After 24 h of BA exposure, culture inserts were washed twice with PBS and transferred to a new 24-wells plate. Lucifer Yellow CH dilithium salt (J0259, Sigma) was dissolved in phenol red-free medium (Gibco) to 1 mg/mL and 100 μL was added to the apical compartment. In the basolateral compartment, 700 μL phenol red-free DMEM was added and afterwards the plate was incubated at 37 °C/5% CO₂ for 3 h. Subsequently, 100 μL of the basolateral compartment was collected and fluorescence was measured at 425/515 nm (excitation/emission). An empty cell culture insert served as a control for complete paracellular permeability.
2.5. RNA isolation and qRT-PCR

The cell culture inserts of plate 2 were washed twice with ice-cold PBS and subsequently, 200 μL TRizol reagent (ThermoFisher) was added per insert. The duplicates per condition were pooled to assure enough RNA yield. RNA was isolated using phenol/chloroform extraction. The RNA concentration was measured using a Nanodrop (Nanodrop ND-1000, Nanodrop Products, Maarssen, The Netherlands). A total of 1000 ng RNA was reverse transcribed using the RevertAid First Strand cDNA Synthesis kit (ThermoFisher). Real-time quantitative PCR was carried out using the SensiMix SYBR kit (Bioline, Alphen aan den Rijn, The Netherlands) in a CFX384 machine (Bio-Rad). Primer sequences are listed in Table 1. Data was normalized against the housekeeping gene GAPDH.

2.6. Protein isolation and western immunoblotting

The cell culture inserts were washed twice with ice-cold PBS and 100 μL RIPA buffer (ThermoFisher) enriched with protease- and phosphatase inhibitors (Roche Diagnostics) was added per culture insert. Duplicates were pooled to assure enough protein yield. Cell lysates were incubated on ice for 20 min following centrifugation for 10 min at 13,000 g. Protein concentrations of the supernatants were measured using a bicinchoninic acid assay (ThermoFisher). For each sample, 14.8 μg protein was loaded on a 4–15% Mini-PROTEAN TGX Precast gel (Bio-Rad). Proteins were separated by SDS gel electrophoresis and transferred onto a polyvinylidene difluoride (Trans-Blot Turbo Midi 0.2 μm PVDF Transfer Packs, Bio-Rad) membrane using the Transblot Turbo System (Bio-Rad). After blocking for 1 h at room temperature, the membranes were incubated overnight at 4 °C with anti-ZO1 (Abcam ab216880), anti-OCLN (Abcam ab16327) and anti-HSP90 (Cell Signaling Technology 4874). ZO1 and OCLN antibodies were used in 1:1000 and for HSP90 1:5000 was used. Subsequently, membranes were incubated with HRP conjugated goat anti-rabbit IgG antibody (1:5000) (GenScript A00098) for 1 h at room temperature. All membrane incubations were in Tris-buffered saline with 0.1% Tween 20 (TBS-T) and 5% (w/v) skimmed dry milk. Washing in between steps was done in TBS-T. Blots were visualized with a fluorescent goat anti-rabbit IgG antibody (1:5000) (GenScript A00098) for 1 h (Abcam ab216327) and anti-HSP90 (Cell Signaling Technology 4874). proteins.

2.7. Cytokine measurements

Medium collected from the basolateral compartments was used for the assessment of cytokines. Levels of IL-6, IL-12/IL-23 p40 and TNF-α were measured with human DuoSet ELISA Development kits (R&D Systems, Abingdon, UK) following the manufacturer's instructions.

2.8. Statistical analysis

Data is presented as mean ± standard deviation (SD). GraphPad Prism version 5 (San Diego, CA, USA) was used for the statistical analyses. Differences between the control and BA-exposed groups were evaluated using an unpaired Student's t-test, unless stated otherwise. A value of p < 0.05 was considered as statistically significant. A total of three biological replicates were performed.

3. Results

3.1. Establishment of an inflammatory in vitro human intestinal model consisting of Caco-2 and HT29-MTX-E12 cells combined with LPS-activated dendritic cells

The first important step of this study was to establish an in vitro human intestinal model with an improved physiological representation of the intestinal barrier and inflammatory environment in the context of IBD. In Figure 1A, a schematic overview of the study design is given.

Table 1. Primer sequences used for qRT-PCR.

| Gene | Forward primer | Reverse primer |
|------|----------------|----------------|
| GAPDH | GAAGGTGAAGGTCGGAGATC | GAAGATGGTGATGAGTTTC |
| OCLN | AGAGGAGGACTATATCCCTA | CGACCTCTGGAAGAACAC |
| ZO1 | AAAGAGGAGGACTATATCCCTA | CGACCTCTGGAAGAACAC |
| CDH1 | CAGCAAGAAGCCGCTGATTTG | GGCAGACAGAGTACAG |
| CCL1 | CTGGGCTGTTCGCTCTGCC | GCGAGTACGTTGGACAG |
| MUC2 | CACCGACATATGCACGTTC | GCGAGAACGAGGAGTTGT |
| MUC5AC | CAGCAAGAACGCTGTTTA | GCGAGAACGAGGAGTTGT |
| DEFB1 | ATGAGAACTTTACCCCTACGGTC | GGACGAATGTCGTGAGT |
| FYZ | GGCAATATTGGAATGGTTG | CGAGCTGAGTACGTTGAA |
| CA12 | ATGAGCACTATTTTATCTGATG | GCGAGTCGTTGGACAG |
| ANG | CTCCATGACAGTATAGCAG | GCGAGTACGTTGGACAG |
| ASB7T | TGTTGCTTCTTCTTGTCG | GCGAGTACGTTGGACAG |
| FABP6 | GGGCAACATATTGACAC | GGGCAACATATTGACAC |
| FGF19 | CACAGGAGGACTATATCCCTA | GGCAGACAGGAGTTGT |
| OSTu | TTACCCGCTGCAAGGAGATC | GGACGAATGTCGTGAGT |
| OSTv | TACCCGCTGCAAGGAGATC | GGACGAATGTCGTGAGT |
| SULT2A1 | CTGGGAAAGGTTAGAACC | AAGGATTGCTTGTCCACATACAT |
3.3. Expression of genes related to intestinal epithelial integrity tended to increase after BA exposure

To further investigate the effects of sulfated secondary BAs on intestinal barrier function, we measured the expression of proteins related to intestinal epithelial integrity. In line with the significant TEER reduction (Figure 2A), lower protein levels of Occludin (OCLN) and Zonula Occludens-1 (ZO1) were measured in cells exposed to activated DCs compared to the control cells without DCs (Figure 2C,D), but these differences were not significant. Next, we investigated whether these lower protein levels were the result of decreased mRNA levels. However, OCLN and ZO1 mRNA levels were not significantly affected by the presence of activated DCs in the basolateral compartment (Figure 2E,F). Other genes related to intestinal barrier function, E-cadherin (CDH1) and Claudin-1 (CLDN1), were also not affected (Figure 2G,H). Interestingly, protein levels of OCLN and ZO1 were not affected by BA exposure, whereas expression of OCLN, ZO1, CDH1 and CLDN1 followed an increasing trend after exposure to most BAs, although these differences were not significant (Figure 2C-H). Together, these results indicate that differences in intestinal barrier function measured by TEER were partly reflected at gene and protein level.

3.4. Differential expression of FXR-target genes by unsulfated, but not sulfated secondary BAs

Next, we aimed to find out if exposure to sulfated and unsulfated secondary BAs resulted in activation of FXR. While DCA and LCA are potent activators of FXR [22], it is unknown whether the sulfated forms
of these BAs also activate FXR, as these BAs are not, or poorly absorbed by enterocytes [23]. To this end, we investigated if exposure to DCA, LCA and their sulfated forms resulted in differential expression of a selection of FXR-target genes: ileal bile acid binding protein (IBABP, FABP6), fibroblast growth factor 19 (FGF19), basolateral organic solute transporters alpha and beta (OSTα/β, SLC5A/B), apical bile salt transporter (ASBT, SLC10A2) and sulfotransferase family 2A member 1 (SULT2A1). Interestingly, the addition of activated DCs potently reduced the expression of ASBT (p < 0.05) and SULT2A1 (p < 0.001) (Figure 3A, F). ASBT was not differentially expressed by any of the BAs (Figure 3A). In contrast, FABP6, FGF19 and OSTβ were significantly upregulated in cells exposed to DCA compared to the control with activated DCs (Figure 3B,C, E). Interestingly, exposure to 100 μM DCA reduced SULT2A1 expression compared to the control cells with DCs (Figure 3F). Altogether, these results indicate that DCA had pronounced effects on the expression of most FXR-target genes, while LCA did not have a significant effect. Exposure to neither sulfated DCA nor sulfated LCA resulted in a differential expression of any FXR-target genes.
Importantly, mRNA levels of ASBT and SULT2A1 were significantly decreased by the presence of basolateral activated DCs.

3.5. No effects of sulfated secondary BAs on MUC2 and MUC5AC expression

In order to determine if sulfated secondary BAs had an effect on the mucus layer, we investigated the expression of MUC2, which is the most dominant gel-forming mucin present in the intestine. Moreover, we also measured expression of MUC5AC. This is another gel-forming mucin which is normally not secreted in the intestine, but is secreted in HT29-MTX-E12 cells, even after growing this cell type under SWMS conditions [29, 30]. Interestingly, the presence of activated DCs decreased the expression of MUC2 and MUC5AC, although this effect was not statistically significant (Figure 4A,B). Compared to the control with activated DCs, the expression of MUC2 seemed to increase after exposure to 100 μM DCA and 10 μM LCA, which was borderline significant (p = 0.06 and p = 0.08), respectively (Figure 4A). Sulfated BA exposure did not have any effect on mucin mRNA expression.

3.6. Subtle effect of some BAs on expression of genes encoding for antimicrobial peptides

Antimicrobial peptides (AMPs) play an important role in intestinal innate immune defense and are known to be produced by enterocytes [35]. We measured the expression of genes encoding the AMPs defensin β-1 (DEFB1) and lysozyme (LYZ), but also angiogenin (ANG) and carbonic anhydrase 12 (CA12), since the latter two AMPs are regulated by the BA receptor FXR [36, 37]. Exposure to BAs caused slight, but non-significant changes compared to the control with activated DCs.

Figure 4. Expression of mucin and antimicrobial peptides. A) Expression of Mucin 2 (MUC2) and B) Mucin 5AC (MUC5AC) and genes encoding the antimicrobial peptides (C–F) defensin β-1 (DEFB1), lysozyme (LYZ), carbonic anhydrase 12 (CA12) and angiogenin (ANG). Expression of genes of interest is expressed relative to the control (Caco-2 and HT29-MTX-E12 cells exposed to activated DCs in basolateral compartment). *p < 0.05 compared to condition with activated DCs.
(Figure 4C-F). Only ANG was significantly lower expressed after exposure to both 100 μM sulfated DCA and DCA, as well as 50 μM LCA (p < 0.05) (Figure 4F).

3.7. No indirect effects of BA exposure on cytokine production by basolateral DCs

Although the presence of activated DCs in the basolateral compartment resulted in a significant increase in permeability of the Caco-2/HT29-MTX-E12 co-culture, apical exposure to sulfated and unsulfated secondary BAs did not have a major additional effect on intestinal epithelial integrity (Figure 2A,B). We hypothesized that BAs might have migrated from the apical to the basolateral compartment via the openings between the intestinal epithelial cells, caused by the increased intestinal permeability. In that case, BAs might have come in contact with the DCs present in the basolateral compartment. Therefore, we investigated if this potential indirect contact between BAs and DCs caused an altered immune response by DCs. To this end, TNF-α and IL-12p40 levels were measured in conditioned medium from basolateral DCs after apical exposure to the different BAs. No differences in either TNF-α or IL-12p40 levels were found (Figure 5A,B).

3.8. Decreasing, but no significant trend in TNF-α and IL-12p40 production by activated DCs after direct exposure to secondary BAs

The finding that cytokine production by DCs was not affected by indirect BA exposure could either indicate that BAs were not migrated towards the basolateral compartment, or that DCs were not affected by BA exposure in terms of TNF-α and IL-12p40 production. To investigate if direct exposure to BAs caused an effect on immune response in DCs, we exposed activated DCs directly to sulfated and unsulfated secondary BAs under similar conditions as previous experiments with indirect exposure. DCA caused a decrease in both TNF-α and IL-12p40 levels compared to the control cells (Figure 5C,D), but these differences were not significant. Lower IL-12p40 levels were found after LCA exposure, albeit variation between biological replicates was high (Figure 5D, Supplementary file 1). No significant differences were found after exposure to sulfated BAs.

4. Discussion

The rising prevalence of IBD in many countries is alarming, given the concomitant increase in social and economic burden associated with this disease [38]. To decrease this burden, it is of utmost importance to better understand the underlying causes of IBD, especially because the etiology of IBD is still largely unknown. Emerging evidence suggests a potential role for BA dysmetabolism in IBD, however, the exact effects of elevated levels of IBD-associated BA subtypes are not widely investigated yet. In the present study, we aimed to investigate the effects of sulfated secondary BAs on intestinal barrier function in the context of IBD. Furthermore, we also investigated if sulfated BAs had an effect on immune response in human monocyte-derived DCs.

We first aimed to establish an inflammatory in vitro human intestinal model, as existing models often insufficiently reflect the chronic inflammatory state in the context of IBD. For example, many existing models either add a cytokine cocktail to induce a pro-inflammatory state [39, 40] or use THP-1 cells as representation of immune cells [41, 42, 43, 44, 45, 46]. The effectiveness of this cell line in an intestinal model is questionable. In two studies, Caco-2 cells exposed to THP-1 cells were severely damaged after 48 h, which was reflected by the high cytotoxicity values and TEER decrease of more than 80% [44, 46]. Given the crucial role of intestinal DCs in IBD pathophysiology [14, 47], we used human monocyte-derived DCs in our model. After activation with LPS, these DCs

Figure 5. Cytokine levels produced by basolateral DCs after indirect BA exposure (via cell culture inserts) and direct exposure. A) TNF-α and B) IL-12p40 levels after indirect exposure. C) TNF-α and D) IL-12p40 levels after direct exposure. Cytokine levels are expressed as percentage of the control, i.e. DCs exposed to only medium.
produced high cytokine levels, resulting in an increased epithelial permeability without affecting cytotoxicity. To improve the physiological representativeness of our model even more, we also paid special attention to the mucus layer, since it is often underrepresented or even lacking in most existing intestinal in vitro models. Therefore, we cultured the Caco-2/HT29-MTX-E12 co-culture under SWMS conditions, which was shown to improve the quantity and quality of the mucus layer [29, 30]. Importantly, the use of in vitro models has some limitations, e.g., with regard to the translatability of the in vivo situation. However, we deemed our model suitable at this, more explorative phase, of our study.

After successful optimization, we exposed the inflammatory in vitro human intestinal immune model to sulfated and unsulfated secondary BAs for 24 h and investigated the effects on intestinal barrier function. We found a slight TEER restoration after exposure to LCA and sulfated DCA, but not DCA and sulfated LCA. These effects on intestinal epithelial barrier integrity were partly reflected at protein level. Previous in vitro studies also showed TEER restoration by LCA in the presence of intestinal inflammatory conditions [40, 48]. With regard to DCA, we did not find an effect on TEER, while a marked increased permeability caused by DCA was observed in several in vitro models [49, 50, 51, 52] as well as in mice [51, 53]. Importantly, we confirmed successful administration of DCA by measuring differential expression of FXR-target genes. Differences in incubation duration and BA concentrations might have impeded direct comparison to existing literature and results of the current study.

In line with the minor effects on intestinal epithelial barrier integrity, we did not find an effect of sulfated BAs on MUC2 and MUC5AC expression. On the contrary, DCA and LCA exposure resulted in an increased expression of MUC2, which was borderline significant. As MUC2 plays a crucial role in intestinal barrier protection [55, 56, 57, 58], increased MUC2 mRNA expression might indicate that these BAs have a restorative effect on the mucus layer. In several human colon cancer cell lines, DCA also increased MUC2 expression [59, 60], but no effects of LCA on mucus mRNA expression have been described. Importantly, it was previously shown that prolonged exposure to pro-inflammatory cytokines strongly decreased mucin gene expression [61, 62]. These results are in line with the decreasing trend in MUC2 and MUC5AC expression that we found after exposure to activated DCs, although this effect was not significant. Next to the effects of BAs on the mucus barrier, it is also important to consider other intestinal barrier properties, such as AMPs that are excreted in the mucus layer [63]. Although DCA was previously shown to increase the expression and secretion of DEFB1/DEFB1 in vitro [64], we were not able to reproduce these results. We did find a slightly reduced expression of ANG by some BAs, which might imply that these BAs have a negative effect on mucosal defense [65]. However, the effects of BAs on AMPs are underexplored in current literature, indicating that more research is needed in this field.

Secondary BAs could have anti-inflammatory effects during intestinal inflammation [27, 66, 67]. Since intestinal DCs are able to sample luminal content [47, 68], we hypothesized that luminal BAs could come in contact with DCs, which might result in an altered immune response. Indeed, direct exposure to secondary BAs caused a decreasing trend in cytokine production, but this effect was less visible after exposure to sulfated secondary BAs. This finding might suggest that increased levels of sulfated BAs at the expense of secondary BAs could abolish the anti-inflammatory effects of secondary BAs. Similar effects were previously found in Caco-2 exposed to sulfated LCA [3], although this effect was found after exposure to relatively high concentrations of LCA and sulfated LCA (400 and 500 μM), which might hamper the physiological translatability of these results.

Here, we present a novel and physiological relevant in vitro human intestinal model representing a pro-inflammatory state, which can be used to study intestinal barrier function in the presence of intestinal inflammation. We used this model to investigate the effects of sulfated and unsulfated secondary BAs on intestinal barrier function and immune response in DCs. We show that these BAs had ambiguous effects on intestinal barrier integrity, as reflected by the minor effects on TEER, expression of intestinal epithelial integrity related genes, AMPs and MUC2. Although more research is needed, our results hint towards anti-inflammatory effects of secondary BAs, but not sulfated secondary BAs on activated DCs. Future research should focus on the relevance of proper bacterial desulphation activity to assure the anti-inflammatory effects of secondary BAs.

Declarations

Author contribution statement

Bente van der Lugt: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Wrote the paper.

Maartje C.P. Vos, Machteld Groote Bromhaar: Performed the experiments.

Noortje Ijsennagger, Jocelijn Meijerink, Wilma T. Steegenga: Conceived and designed the experiments.

Frank Vrielings: Conceived and designed the experiments; Contributed reagents, materials, analysis tools or data.

Funding statement

This work was supported by the Nutricia Research Foundation with grant no. 2018-25. Bente van der Lugt was supported by the NWO Graduate Programme on Food Structure, Digestion and Health (022.006.009). Noortje Ijsennagger was supported by the MLDS career development grant (CDG16-04) and by the Wilhelmina Children’s Hospital Research Fund.

Data availability statement

Data included in article/supplementary material/referenced in article.

Declaration of interests statement

The authors declare no conflict of interest.

Additional information

Supplementary content related to this article has been published online at https://doi.org/10.1016/j.helyon.2022.e08883.

References

[1] D.C. Baumgart, W.J. Sandborn, Inflammatory bowel disease: clinical aspects and established and evolving therapies, Lancet 369 (9573) (2007) 1641–1657.
[2] A. Kaser, S. Zeitzig, R.S. Blumberg, Inflammatory bowel disease, Annu. Rev. Immunol. 28 (2010) 573–621.
[3] H. Duboc, S. Rajca, D. Raineault, D. Benarous, M.A. Maubert, E. Quervain, et al., Connecting dysbiosis, bile acid metabolism and gut inflammation in inflammatory bowel diseases, Gut 62 (4) (2013) 531–539.
[4] D.N. Frank, A.L. St Amand, R.A. Feldman, E.C. Boedeker, N. Harpaz, N.R. Pace, Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, Proc. Natl. Acad. Sci. U. S. A. 104 (34) (2007) 13780–13785.
[5] D. Gevers, S. Kugathasan, L.A. Denson, Y. Vázquez-Baeza, W. Van Treuren, B. Ren, et al., The treatment-naive microbiome in new-onset Crohn’s disease, Cell Host Microbe. 15 (3) (2014) 382–392.
[6] K. Nishino, A. Nishida, R. Inoue, Y. Kawada, M. Ohno, S. Sakai, et al., Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease, J. Gastroenterol. 53 (1) (2018) 95–106.
[7] G. Morris, M. Berk, A.F. Carvalho, J.R. Caso, Y. Sano, M. Maes, The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimmune processes with an emphasis on inflammatory bowel disease type 1 diabetes and chronic fatigue syndrome, Curr. Pharmaceut. Res. Des. 22 (40) (2016) 6058–6075.
[8] C.K. Hazlewood, M.C. Cook, R. Eri, G.R. Price, S.B. Tauro, D. Taupin, et al., Aberrant mucus assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis, PLoS Med. 5 (3) (2008) e54.
E.A. Franzosa, A. Sirota-Madi, J. Avila-Pacheco, N. Fornelos, H.J. Haiser, S. Reinker, et al., Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice, Cell Host Microbe. 12 (2) (2012) 139–152.

H. Schmitz, C. Barmeyer, M. Fromm, N. Runke, H.D. Foss, C.J. Bestel, et al., Altered tight junction function is associated with the impaired epithelial barrier function in ulcerative colitis, Gastroenterology 116 (2) (1999) 301–309.

B.R. Sartor, Microbial influences in inflammatory bowel diseases, Gastroenterology 143 (2007) 577–594.

R.J. Xavier, D.K. Podolsky, Unravelling the pathogenesis of inflammatory bowel disease, Nature 448 (7152) (2007) 427–434.

O. Bernardo, M. Chaparro, J.P. Gisbert, Human intestinal dendritic cells in inflammatory bowel disease, Mol. Nutr. Food Res. 57 (7) (2013), e1709011.

V. Cerovic, S.A. Houston, C.L. Scott, A. Aumeunier, U. Yrlid, A.M. Mowat, et al., Cell death and miRNA expression in dendritic cells is influenced by the gut microbiome in ulcerative colitis, Gut 66 (2) (2017) 242–254.

A. Konrad, Y. Gong, W. Duck, R. Bavaza, G.O. Elson, Tight mucosal compartmentation of the murine immune response to antigens of the enteric microbiota, Gastroenterology 130 (7) (2006) 2050–2059.

M. Bhat, L. Chapuy, N. Babi, M. Robio, B. Paniro, R. Wensel, et al., Differential accumulation and function of proinflammatory 6-sulfo LacNAc dendritic cells in lymph node and colon of Crohn’s versus ulcerative colitis patients, J. Leukoc. Biol. 98 (4) (2015) 671–681.

S.C. Ng, J.L. Benjamin, N.E. McCarthy, C.R. Hedlin, A. Koutsoumpas, S. Flambond, et al., Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn’s disease, Inflamm. Bowel Dis. 17 (10) (2011) 2027–2037.

E.A. Franza, A. Sirota-Madi, J. Avila-Pacheco, N. Fornelos, H.D. Haiser, S. Reinker, et al., Gut microbiome structure and metabolic activity in inflammatory bowel disease, Nat. Microbiol. 4 (2019) 293–302.

J.P. Jacobs, M. Goudarzi, N. Singh, M. Tong, I.H. McHardy, P. Ruegger, et al., A disease-associated microbial and metabolomics state in relatives of pediatric inflammatory bowel disease patients, Cell Mol. Gastroenterol. Hepatol. 2 (6) (2019), e25666.

S. Wang, R. Martins, M.C. Sullivan, E.S. Friedman, A.M. Misic, A. El-Fahmawi, et al., Dietary intervention in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids, Microbiome 7 (1) (2019) 126.

J.Y. Chiang, Bile acid metabolism and signaling, Compr. Physiol. 3 (3) (2013) 1191–1212.

I. Alouzis, Bile Acid Sulfation: a Pathway of Bile Acid Elimination and Detoxification, Toxicol. Sci. 108 (2) (2009) 225–246.

M.L. Jones, C.J. Martoni, J.G. Ganaopoly, A. Labbé, S. Prakash, The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention, Expert Opin. Biol. Ther. 14 (13) (2014) 467–482.

M. Bier, H. Delgrazievre, H. Duboc, P. Jouret, B. Cavin, L. Brot, et al., Intercellular bile acid metabolism and microbiota states in relation to pediatric inflammatory bowel disease patients, Cell Mol. Gastroenterol. Hepatol. 2 (6) (2019), e25666.

S. Wang, R. Martins, M.C. Sullivan, E.S. Friedman, A.M. Misic, A. El-Fahmawi, et al., Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids, Microbiome 7 (1) (2019) 126.

J.Y. Chiang, Bile acid metabolism and signaling, Compr. Physiol. 3 (3) (2013) 1191–1212.

J. Alouzis, Bile Acid Sulfation: a Pathway of Bile Acid Elimination and Detoxification, Toxicol. Sci. 108 (2) (2009) 225–246.

S. Wang, R. Martins, M.C. Sullivan, E.S. Friedman, A.M. Misic, A. El-Fahmawi, et al., Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids, Microbiome 7 (1) (2019) 126.

J.Y. Chiang, Bile acid metabolism and signaling, Compr. Physiol. 3 (3) (2013) 1191–1212.

J. Alouzis, Bile Acid Sulfation: a Pathway of Bile Acid Elimination and Detoxification, Toxicol. Sci. 108 (2) (2009) 225–246.

S. Wang, R. Martins, M.C. Sullivan, E.S. Friedman, A.M. Misic, A. El-Fahmawi, et al., Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids, Microbiome 7 (1) (2019) 126.

J.Y. Chiang, Bile acid metabolism and signaling, Compr. Physiol. 3 (3) (2013) 1191–1212.

J. Alouzis, Bile Acid Sulfation: a Pathway of Bile Acid Elimination and Detoxification, Toxicol. Sci. 108 (2) (2009) 225–246.

S. Wang, R. Martins, M.C. Sullivan, E.S. Friedman, A.M. Misic, A. El-Fahmawi, et al., Diet-induced remission in chronic enteropathy is associated with altered microbial community structure and synthesis of secondary bile acids, Microbiome 7 (1) (2019) 126.

J.Y. Chiang, Bile acid metabolism and signaling, Compr. Physiol. 3 (3) (2013) 1191–1212.
[65] L.V. Hooper, T.S. Stappenbeck, C.V. Hong, J.I. Gordon, Angiogenins: a new class of microbicidal proteins involved in innate immunity, Nat. Immunol. 4 (3) (2003) 269–273.

[66] X. Song, X. Sun, S.F. Oh, M. Wu, Y. Zhang, W. Zheng, et al., Microbial bile acid metabolites modulate gut RORγ(+) regulatory T cell homeostasis, Nature 577 (7790) (2020) 410–415.

[67] J.B.J. Ward, N.K. Lajczak, O.B. Kelly, A.M. O'Dwyer, A.K. Giddam, J. Ng, et al., Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon, Am. J. Physiol. Gastrointest. Liver Physiol. 312 (6) (2017) G550–G558.

[68] O. Schulz, O. Pabst, Antigen sampling in the small intestine, Trends Immunol. 34 (4) (2013) 155–161.